−2.45USD
−10.52 MUSD
152.43 KUSD
8.68 M
About ABVC BioPharma, Inc.
Sector
CEO
Uttam Yashwant Patil
Headquarters
Fremont
Website
Employees (FY)
19
Founded
1990
FIGI
BBG000Q844Z2
ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. The firm's product pipeline includes ABV-1501, which is a combination therapy for triple negative breast cancer, ABV-1504, which is a botanical reuptake inhibitor that targets norepinephrine, ABV-1505 for treating attention deficit hyperactivity disorder, ABV-1702 to treat myelodysplastic syndromes, ABV-1703 for Pancreatic Cancer, ABV-1601 for treating depression in cancer patients, ABV-1701, which is a vitreous substitute for vitrectomy, ABV-2001, and ABV-2002. The company was founded in 1990 and is headquartered in Fremont, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of ABVC is 1.31 USD — it has increased by 26.26% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange ABVC BioPharma, Inc. stocks are traded under the ticker ABVC.
ABVC BioPharma, Inc. is going to release the next earnings report on May 13, 2024. Keep track of upcoming events with our Earnings Calendar.
ABVC stock is 37.00% volatile and has beta coefficient of −1.03. Check out the list of the most volatile stocks — is ABVC BioPharma, Inc. there?
ABVC earnings for the last quarter are −1.50 USD per share, whereas the estimation was −1.50 USD resulting in a 0% surprise. The estimated earnings for the next quarter are −0.40 USD per share. See more details about ABVC BioPharma, Inc. earnings.
ABVC BioPharma, Inc. revenue for the last quarter amounts to 589.78 K USD despite the estimated figure of 26.44 K USD. In the next quarter revenue is expected to reach 300.00 K USD.
Yes, you can track ABVC BioPharma, Inc. financials in yearly and quarterly reports right on TradingView.
ABVC stock has risen by 23.88% compared to the previous week, the month change is a 22.72% rise, over the last year ABVC BioPharma, Inc. has showed a 81.33% decrease.
ABVC net income for the last quarter is −3.11 M USD, while the quarter before that showed −3.32 M USD of net income which accounts for 6.23% change. Track more ABVC BioPharma, Inc. financial stats to get the full picture.
Today ABVC BioPharma, Inc. has the market capitalization of 10.98 M, it has decreased by 10.94% over the last week.
No, ABVC doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, ABVC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ABVC BioPharma, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 23, 2024, the company has 19.00 employees. See our rating of the largest employees — is ABVC BioPharma, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ABVC BioPharma, Inc. technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ABVC BioPharma, Inc. stock shows the sell signal. See more of ABVC BioPharma, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ABVC BioPharma, Inc. EBITDA is −8.19 M USD, and current EBITDA margin is −5.37 K%. See more stats in ABVC BioPharma, Inc. financial statements.